Table 3.
Multivariate analysis for survival in all patients/margin positive patients
| All patients Variable | HR | P value | Margin positive HR | P value |
| Tx sequence | ||||
| No surgery | Reference | Reference | N/A | N/A |
| NAT/NEG | 0.48 | <0.001 | N/A | N/A |
| NAT/POS | 0.71 | <0.001 | Reference | Reference |
| AT/NEG | 0.54 | <0.001 | N/A | N/A |
| AT/POS | 0.77 | <0.001 | 1.03 | 0.65 |
| SURG/NEG | 0.88 | <0.001 | N/A | N/A |
| SURG/POS | 1.71 | <0.001 | 2.44 | <0.001 |
| Sex | ||||
| Male | N/A (UVA) | N/A (UVA) | Reference | Reference |
| Female | N/A (UVA) | N/A (UVA) | 0.97 | 0.57 |
| Age group (years) | ||||
| 18–49 | Reference | Reference | N/A (UVA) | N/A (UVA) |
| 50–69 | 1.06 | 0.16 | N/A (UVA) | N/A (UVA) |
| 70–84 | 1.21 | <0.001 | N/A (UVA) | N/A (UVA) |
| 85+ | 1.31 | <0.001 | N/A (UVA) | N/A (UVA) |
| Charlson | ||||
| 0 | Reference | Reference | Reference | Reference |
| 1 | 1.09 | <0.001 | 1.19 | <0.001 |
| 2+ | 1.32 | <0.001 | 1.46 | <0.001 |
| Tumour size | ||||
| 2 cm or less | Reference | Reference | Reference | Reference |
| 2.1–5 cm | 1.41 | <0.001 | 1.26 | <0.001 |
| >5 cm | 1.57 | <0.001 | 1.40 | <0.001 |
| Tumour ocation | ||||
| Head | Reference | Reference | Reference | Reference |
| Body | 0.97 | 0.44 | 1.08 | 0.38 |
| Tail | 0.91 | 0.007 | 0.94 | 0.27 |
| Duct | 0.64 | 0.001 | 0.82 | 0.34 |
| Other | 0.93 | 0.035 | 0.93 | 0.14 |
| Clinical nodes | ||||
| Negative | Reference | Reference | Reference | Reference |
| Positive | 1.05 | 0.35 | 1.01 | 0.84 |
| Grade | ||||
| 1 | Reference | Reference | Reference | Reference |
| 2 | 1.30 | <0.001 | 1.25 | 0.005 |
| 3 | 1.74 | <0.001 | 1.55 | <0.001 |
| 4 | 1.56 | <0.001 | 1.08 | 0.77 |
| Clinical stage | ||||
| IIA (T3N0) | Reference | Reference | Reference | Reference |
| IIB (T1-3N1) | 1.21 | 0.001 | 1.11 | 0.34 |
| III (T4N0-1) | 1.26 | <0.001 | 1.47 | <0.001 |
| Path stage group | ||||
| IA | Reference | Reference | Reference | Reference |
| IB | 0.85 | 0.68 | N/A (UVA) | N/A (UVA) |
| IIA | 1.38 | 0.32 | N/A (UVA) | N/A (UVA) |
| IIB | 1.09 | 0.79 | N/A (UVA) | N/A (UVA) |
| III | 1.29 | 0.44 | N/A (UVA) | N/A (UVA) |
| IV | 2.16 | 0.017 | N/A (UVA) | N/A (UVA) |
| Chemoradiation | ||||
| Chemo only | Reference | Reference | Reference | Reference |
| Chemoradiation | 0.89 | <0.001 | 0.78 | <0.001 |
| Chemo number | ||||
| Single agent | Reference | Reference | Reference | Reference |
| Multiagent | 0.92 | <0.001 | 0.93 | 0.199 |
AT, adjuvant therapy; chemo, chemotherapy; N/A (UVA), did not meet requirement for significance on UVA; N/A (UVA), did not meet requirement for significance on UVA; NAT, neoadjuvant therapy; NEG, negative; path, pathology; POS, positive; Surg, surgery; Tx, treatment.